EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Effectiveness and Safety of Tildrakizumab in Psoriasis Patients Who Failed Anti-IL17 Treatment: A 28-Week Real-Life Study

Matteo Megna, Angelo Ruggiero iD, Nello Tommasino iD, Claudio Brescia, Fabrizio Martora iD, Sara Cacciapuoti, Luca Potestio iD

Clinical, Cosmetic and Investigational Dermatology · 2024-05 · Volume 17 · 1037-1042

DOI: 10.2147/ccid.s464326 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical, Cosmetic and Investigational Dermatology, 2024-05. Verfasst von Matteo Megna und 6 weiteren Autor:innen. Beteiligte Einrichtung: Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

Tildrakizumabanti-IL23psoriasisreal-life

Autor:innen und Institutionen

  • Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.

ORCID-Profile: Angelo Ruggiero, Nello Tommasino, Fabrizio Martora, Luca Potestio

Zitieren

APA

Megna, M., Ruggiero, A., Tommasino, N., Brescia, C., Martora, F., Cacciapuoti, S., & Potestio, L. (2024). Effectiveness and Safety of Tildrakizumab in Psoriasis Patients Who Failed Anti-IL17 Treatment: A 28-Week Real-Life Study. Clinical, Cosmetic and Investigational Dermatology, Volume 17, 1037-1042. https://doi.org/10.2147/ccid.s464326

Vancouver

Megna M, Ruggiero A, Tommasino N, Brescia C, Martora F, Cacciapuoti S, et al. Effectiveness and Safety of Tildrakizumab in Psoriasis Patients Who Failed Anti-IL17 Treatment: A 28-Week Real-Life Study. Clinical, Cosmetic and Investigational Dermatology. 2024;Volume 17:1037-1042. doi:10.2147/ccid.s464326

BibTeX
@article{Megna2024,
  author = {Megna, Matteo and Ruggiero, Angelo and Tommasino, Nello and Brescia, Claudio and Martora, Fabrizio and Cacciapuoti, Sara and Potestio, Luca},
  title = {Effectiveness and Safety of Tildrakizumab in Psoriasis Patients Who Failed Anti-IL17 Treatment: A 28-Week Real-Life Study},
  journal = {Clinical, Cosmetic and Investigational Dermatology},
  year = {2024},
  volume = {Volume 17},
  pages = {1037--1042},
  doi = {10.2147/ccid.s464326}
}
Kostenlos starten →